Guided Therapeutics (GTHP) Stock Price, News & Analysis

Company Overview

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.

Key Stats

• Today's Range: $0.13 to $0.14
• 50-Day Range: $0.10 to $0.19
• 52-Week Range: $0.06 to $0.25
• Volume: 2,004 shs
• Average Volume: 22,354 shs
• Market Capitalization: $8.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Guided Therapeutics Stock Analysis - MarketRank™

Guided Therapeutics scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Guided Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Guided Therapeutics is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Guided Therapeutics is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the outstanding shares of Guided Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Guided Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Guided Therapeutics has recently increased by 36.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Guided Therapeutics does not currently pay a dividend.

Dividend Growth

Guided Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.02% of the outstanding shares of Guided Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Guided Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Guided Therapeutics has recently increased by 36.46%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -1.00

News Sentiment

Guided Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Guided Therapeutics this week, compared to 0 articles on an average week.

MarketBeat Follows

2 people have added Guided Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Guided Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

66.83% of the stock of Guided Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.69% of the stock of Guided Therapeutics is held by institutions.

GTHP Stock Analysis - Frequently Asked Questions

How have GTHP shares performed this year?

Guided Therapeutics' stock was trading at $0.1535 at the start of the year. Since then, GTHP shares have decreased by 8.8% and is now trading at $0.14.
View the best growth stocks for 2024 here.

How were Guided Therapeutics' earnings last quarter?

Guided Therapeutics, Inc. (OTCMKTS:GTHP) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.01) EPS for the quarter.

How do I buy shares of Guided Therapeutics?

Shares of GTHP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Guided Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Guided Therapeutics investors own include Cornerstone Strategic Value Fund (CLM), Intel (INTC), Beam Therapeutics (BEAM), ChargePoint (CHPT), CSX (CSX), Warner Bros. Discovery (DISCA) and Enbridge (ENB).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 10/15/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:GTHP
• CUSIP: N/A
• CIK: 924515
• Web: www.guidedinc.com
• Phone: (770) 242-8723
• Fax: 770-242-8639
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-3,490,000.00
• Net Margins: N/A
• Pretax Margin: -5,721.05%
• Return on Equity: N/A
• Return on Assets: -138.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.18
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $100,000.00
• Price / Sales: 84.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.13) per share
• Price / Book: -1.08

Miscellaneous

• Outstanding Shares: 60,460,000
• Free Float: 18,948,000
• Market Cap: $8.46 million
• Optionable: Not Optionable
• Beta: 0.52